AtriCure (NASDAQ:ATRC) Director Sells 3,500 Shares

Key Points

• AtriCure Director Maggie Yuen sold 3,500 shares at an average price of $38.42, receiving $134,470 and reducing her direct stake by nearly 20% to 14,015 shares.
• AtriCure reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding analysts’ revenue estimate of $151.8 million. The company set fiscal 2026 EPS guidance at $0.24–$0.32.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $48.50 versus a recent price of $40.60.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the sale, the director directly owned 14,015 shares of the company's stock, valued at $538,456.30. The trade was a 19.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

AtriCure Stock Performance

Shares of ATRC stock traded up $1.11 during mid-day trading on Friday, reaching $40.60. 108,527 shares of the company's stock traded hands, compared to its average volume of 800,970. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The firm has a market capitalization of $2.07 billion, a PE ratio of 193.54 and a beta of 1.20. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $43.18. The firm has a 50 day moving average price of $31.98 and a two-hundred day moving average price of $31.31.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts forecast that AtriCure, Inc. will post 0.2 EPS for the current year.

Institutional Trading of AtriCure

A number of hedge funds have recently modified their holdings of ATRC. Oak Harvest Investment Services purchased a new position in AtriCure in the fourth quarter valued at $1,484,000. Massachusetts Financial Services Co. MA raised its position in AtriCure by 20.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 511,213 shares of the medical device company's stock worth $20,224,000 after acquiring an additional 86,532 shares during the period. F m Investments LLC acquired a new stake in shares of AtriCure in the fourth quarter valued at about $2,872,000. Vanguard Group Inc. increased its stake in shares of AtriCure by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company's stock worth $193,993,000 after purchasing an additional 62,861 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of AtriCure during the first quarter worth about $7,922,000. Hedge funds and other institutional investors own 99.11% of the company's stock.

Analysts Set New Price Targets

ATRC has been the subject of a number of research reports. Canaccord Genuity Group increased their price target on AtriCure from $53.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday, May 6th. Citigroup reiterated a "market outperform" rating on shares of AtriCure in a report on Tuesday, July 21st. UBS Group lowered their price target on AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. Finally, Wall Street Zen cut shares of AtriCure from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $48.50.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source